ESMO 2018: Drei neue Studien zu Tumoren im oberen GI-Trakt
Assoz.-Prof. PD Dr. Armin Gerger, Universitätsklinik für Innere Medizin, Graz, diskutiert die wichtigsten neuen Studien zu Magen-, hepatozellulärem und cholangiozellulärem Karzinom.
Quelle: ESMO 2018
Abstracts:
LBA25 – TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer
Hendrik-Tobias Arkenau (London, GB)
615O – Randomized phase III study of Gemcitabine, Cisplatin plus S-1 (GCS) versus Gemcitabine, Cisplatin (GC) for Advanced Biliary Tract Cancer (KHBO1401-MITSUBA)
Daisuke Sakai (Osaka, JP)
LBA26 – Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)
Michael J. Pishvaian (Washington, US)